Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph Pantophlet

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Current Pharmaceutical Design|December 7, 2010
Antibody epitope exposure and neutralization of HIV-1Ralph Pantophlet
Trends in Molecular Medicine|November 8, 2003
Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodiesRalph Pantophlet, Dennis R Burton
Annual Review of Immunology|March 23, 2006
GP120: target for neutralizing HIV-1 antibodiesRalph Pantophlet, Dennis R Burton
Nature Biotechnology|February 10, 2012
Complex binding sites made to orderJamie K Scott, Ralph Pantophlet, Lisa Craig
Journal of Virology|April 30, 2003
Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine designRalph Pantophlet, Ian A Wilson, Dennis R Burton
Vaccine|December 7, 2011
An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding siteFatima K Ahmed, Brenda E Clark, Dennis R Burton, et al.
Journal of the American Chemical Society|April 24, 2019
Synthesis of an Undecasaccharide Featuring an Oligomannosidic Heptasaccharide and a Bacterial Kdo-lipid A Backbone for Eliciting Neutralizing Antibodies to Mammalian Oligomannose on the HIV-1 Envelope SpikeNino Trattnig, Markus Blaukopf, Jean-François Bruxelle, et al.
Human Vaccines|February 10, 2009
Report on the AIDS Vaccine 2008 ConferenceGalit Alter, Jintanat Ananworanich, Ralph Pantophlet, et al.
Journal of Virology|November 28, 2008
The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regionsRalph Pantophlet, Meng Wang, Rowena O Aguilar-Sino, et al.
Journal of Virology|May 14, 2004
Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory workerTim Beaumont, Esther Quakkelaar, Ad van Nuenen, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Current Pharmaceutical Design|December 7, 2010
Antibody epitope exposure and neutralization of HIV-1Ralph Pantophlet
Trends in Molecular Medicine|November 8, 2003
Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodiesRalph Pantophlet, Dennis R Burton
Annual Review of Immunology|March 23, 2006
GP120: target for neutralizing HIV-1 antibodiesRalph Pantophlet, Dennis R Burton
Nature Biotechnology|February 10, 2012
Complex binding sites made to orderJamie K Scott, Ralph Pantophlet, Lisa Craig
Journal of Virology|April 30, 2003
Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine designRalph Pantophlet, Ian A Wilson, Dennis R Burton
Vaccine|December 7, 2011
An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding siteFatima K Ahmed, Brenda E Clark, Dennis R Burton, et al.
Journal of the American Chemical Society|April 24, 2019
Synthesis of an Undecasaccharide Featuring an Oligomannosidic Heptasaccharide and a Bacterial Kdo-lipid A Backbone for Eliciting Neutralizing Antibodies to Mammalian Oligomannose on the HIV-1 Envelope SpikeNino Trattnig, Markus Blaukopf, Jean-François Bruxelle, et al.
Human Vaccines|February 10, 2009
Report on the AIDS Vaccine 2008 ConferenceGalit Alter, Jintanat Ananworanich, Ralph Pantophlet, et al.
Journal of Virology|November 28, 2008
The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regionsRalph Pantophlet, Meng Wang, Rowena O Aguilar-Sino, et al.
Journal of Virology|May 14, 2004
Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory workerTim Beaumont, Esther Quakkelaar, Ad van Nuenen, et al.
Pageof 6